CD274 and non-small cell lung carcinoma: In a phase II trial (ATLANTIC) evaluating durvalumab in EGFR-/ALK-mutated NSCLC, the ORR was 3.6% in PD-L1 < 25% and 12.2% in PD-L1 ≥ 25% patients [108].